Etiroxate, (S)-

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598070

CAS#: 35530-07-5

Description: Etiroxate, (S)- has a lipid-lowering effect.

Chemical Structure

img
Etiroxate, (S)-
CAS# 35530-07-5
Instruction

Theoretical Analysis

MedKoo Cat#: 598070
Name: Etiroxate, (S)-
CAS#: 35530-07-5
Chemical Formula: C18H17I4NO4
Exact Mass: 818.73
Molecular Weight: 818.950
Elemental Analysis: C, 26.40; H, 2.09; I, 61.98; N, 1.71; O, 7.81

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Etiroxate, (S)-;

IUPAC/Chemical Name: ethyl (S)-2-amino-3-(4-(4-hydroxy-3,5-diiodophenoxy)-3,5-diiodophenyl)-2-methylpropanoate

InChi Key: LWZCMKGGFONJPB-SFHVURJKSA-N

InChi Code: InChI=1S/C18H17I4NO4/c1-3-26-17(25)18(2,23)8-9-4-13(21)16(14(22)5-9)27-10-6-11(19)15(24)12(20)7-10/h4-7,24H,3,8,23H2,1-2H3/t18-/m0/s1

SMILES Code: N[C@](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)(C)C(OCC)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 818.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Schwartzkopff W, Hoffmann H, Nijssen J, Etzel V. [The effect of etiroxate on serum lipids after myocardial infarction or in angina pectoris]. Med Klin. 1976 Sep 17;71(38):1555-63. German. PubMed PMID: 185504.

2: Weisweiler P, Schwandt P. Effects of etiroxate on low density and high density lipoproteins in hypercholesterolemic patients. Atherosclerosis. 1981 Apr;39(1):45-9. PubMed PMID: 7247989.

3: Cervinková Z, Simek J, Trojovská V. Effect of triiodothyronine or etiroxate on DNA synthesis in intact and regenerating liver. Physiol Bohemoslov. 1984;33(6):501-6. PubMed PMID: 6241723.

4: Schwartzkopff W, Russ E. [Comparative studies of the lipid-lowering activity of etiroxate hydrochloride and dextrothyroxine (author's transl)]. MMW Munch Med Wochenschr. 1975 May 9;117(19):827-30. German. PubMed PMID: 805950.

5: Dobiásová M, Vítek V, Kopecká J. Effect of etiroxate on LCAT activity and on certain energy metabolism enzymes in the rat. Physiol Bohemoslov. 1982;31(4):323-7. PubMed PMID: 6215662.

6: Knüchel F. [Clinical experience with etiroxate hydrochloride in patients with primary hyperlipoproteinemia]. Med Welt. 1977 Jan 28;28(4):186-9. German. PubMed PMID: 320426.

7: Zadák Z, Kalinová M, Sobotka L. [Etiroxate treatment for hyperlipoproteinaemia type IIa and IIb (author's transl)]. Cas Lek Cesk. 1982 May 14;121(19):593-5. Czech. PubMed PMID: 7093991.

8: Beckmann R. [Expeimental studies in animals on a new lipid lowering compound: etiroxate hydrochloride (author's transl)]. Arzneimittelforschung. 1979;29(3):499-508. German. PubMed PMID: 582735.

9: Dobiásová M, Vondra K, Matousek V, Válek J. Rate of LCAT-mediated cholesterol esterification and serum lipids during etiroxate therapy in hyperlipoproteinemia. Atherosclerosis. 1982 Apr;42(2-3):251-61. PubMed PMID: 7073804.

10: Banz H, Gall FP. [Therapy of hyperlipoproteinemia type IIa and IIb with etiroxate-HCl. Dose-response comparison]. Fortschr Med. 1979 Nov 8;97(42):1942-1947. German. PubMed PMID: 520990.

11: Lageder H, Irsigler K. Reduction of serum lipids by means of etiroxate (Liponorm). Atherosclerosis. 1975 Nov-Dec;22(3):473-84. PubMed PMID: 1212278.

12: Vondra K, Válek J, Dobiásová M, Honzák R. [Type II hyperlipoproteinaemia treated with etiroxate (author's transl)]. Cas Lek Cesk. 1979 Oct 12;118(40-41):1251-5. Czech. PubMed PMID: 527004.

13: Cervinková Z, Simek J, Egrtová I. [The effect of repeated administration of triiodothyronine or etiroxate on liver regeneration in rats after partial hepatectomy]. Sb Ved Pr Lek Fak Karlovy Univerzity Hradci Kralove Suppl. 1985;28(3-4):291-8. Czech. PubMed PMID: 3879914.

14: Schwartzkopff W, Russ E. [Long-term treatment of hyperlipoproteinaemia, types IIa and IIb, with etiroxate (author's transl)]. Dtsch Med Wochenschr. 1975 Apr 11;100(15):815-21. German. PubMed PMID: 164334.

15: Dobiásová M, Vondra K. Cholesterol turnover and risk factors for the development of coronary heart disease. Czech Med. 1982;5(1):16-28. PubMed PMID: 7075390.

16: Canzler H. [Drug therapy of hypercholesterinemias (author's transl)]. MMW Munch Med Wochenschr. 1980 Mar 28;122(13):464-70. German. PubMed PMID: 6769018.

17: Banz H, Gall FP. [Dose-response comparison with etiroxat HCl in hyperlipoproteinemias types IIa and IIb]. Med Klin. 1980 Jan 4;75(1):35-6. German. PubMed PMID: 7366519.